Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QRL-201 multiple ascending dose study in amyotrophic lateral sclerosis
NL-OMON59424Phase 1Active, not recruiting
- Sponsor
- QurAlis
- Start
- Aug 2023
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of QRL-201 in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by QurAlis. Started Aug 2023; status: active, not recruiting.
02
Drugs
QRL-201
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON59424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59424.